These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 8809659)
21. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490 [TBL] [Abstract][Full Text] [Related]
22. Methotrexate, mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer patients. Merlini L; Secondo V; Mammoliti S; Bellotti P; Castello C; Gallo L Anticancer Res; 1994; 14(3B):1423-6. PubMed ID: 8067717 [TBL] [Abstract][Full Text] [Related]
23. A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer. Lin CC; Cheng AL; Hsu CH; Lu YS; Hsu C; Yeh KH; Wu CY; Huang CS; Yang CH Anticancer Res; 2007; 27(1B):641-5. PubMed ID: 17348454 [TBL] [Abstract][Full Text] [Related]
24. Mitoxantrone combined with vincristine, cyclophosphamide and fluorouracil for advanced breast cancer. A study of short-term response rate. Misset JL; Metz R; Gil-Delgado M; Keiling R; Cappelaere P; Armand JP; Prévot G; Grimbert J; Mathé G; Hibberd M Anticancer Res; 1987; 7(4B):737-40. PubMed ID: 3674760 [TBL] [Abstract][Full Text] [Related]
25. Long duration of response with vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy in metastatic breast cancer: a pilot phase II study. Belpomme D; Heritier F; Gisselbrecht C; Marty M; Michaud G; Le Rol A; Cour V; George C; Maral J Cancer Treat Rep; 1987 Sep; 71(9):845-7. PubMed ID: 3621218 [TBL] [Abstract][Full Text] [Related]
26. Vinorelbine and infusional 5-fluorouracil in anthracycline and taxane pre-treated metastatic breast cancer. Stuart NS; McIllmurray MB; Bishop JL; Johnston SR; Price CG; O'Reilly SM; Joffe JK; Neave F; Whipp EC Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):152-6. PubMed ID: 18083354 [TBL] [Abstract][Full Text] [Related]
27. Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer. Yap HY; Blumenschein GR; Hortobagyi GN; Buzdar AU; Schell FC; Bodey GP Am J Clin Oncol; 1982 Oct; 5(5):511-4. PubMed ID: 7180829 [TBL] [Abstract][Full Text] [Related]
28. [Metastatic breast cancer. Chemotherapy with adriamycin, vindesine, cyclophosphamide and 5 FU. Value of continuous 5 FU perfusion. Results of controlled trials]. Jouve M; Palangie T; Belli L; Dorval T; Garcia-Giralt E; Beuzeboc P; Scholl S; Mosseri V; Livartowski A; Vedrenne J Bull Cancer; 1989; 76(6):643-52. PubMed ID: 2673438 [TBL] [Abstract][Full Text] [Related]
29. Mitoxantrone and cyclophosphamide in advanced breast cancer: a pilot study. McDonald DB; Abu-Zahra H; Yoshida S; Binder H Semin Oncol; 1984 Sep; 11(3 Suppl 1):19-22. PubMed ID: 6385260 [TBL] [Abstract][Full Text] [Related]
30. Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. Yen CC; Tung SL; Hsieh RK; Chiou TJ; Liu JH; Wang WS; Chen PM Jpn J Clin Oncol; 1997 Oct; 27(5):316-20. PubMed ID: 9390208 [TBL] [Abstract][Full Text] [Related]
31. [Efficacy of combination chemotherapy with mitoxantrone, vincristine, prednisolone (MVP) for recurrence of breast cancer]. Iba T; Yagi Y; Kidokoro A; Fukunaga M; Momose F Gan To Kagaku Ryoho; 1995 Jan; 22(1):83-6. PubMed ID: 7826082 [TBL] [Abstract][Full Text] [Related]
32. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Yap HY; Blumenschein GR; Keating MJ; Hortobagyi GN; Tashima CK; Loo TL Cancer Treat Rep; 1980; 64(2-3):279-83. PubMed ID: 7407762 [TBL] [Abstract][Full Text] [Related]
33. [Pilot study of chemotherapy with mitoxantrone, ifosfamide, 5-fluorouracil in metastatic cancers of the breast. Preliminary study]. Brun B; Nasr E; Randria G; Feuilhade F; Gimonet JF; Le Bourgeois JP Bull Cancer; 1991 Nov; 78(11):1075-9. PubMed ID: 1369554 [No Abstract] [Full Text] [Related]
34. [Evaluation of regimens for the simultaneous and sequential administration of cytostatics in the combined chemotherapy of disseminated forms of breast cancer]. Korman DB; Borisov AI; Maslova IA; Pines EV Vopr Onkol; 1985; 31(5):21-6. PubMed ID: 3925630 [TBL] [Abstract][Full Text] [Related]
35. Continuous 5-day infusion of vinblastine for percutaneous hepatic arterial chemotherapy for metastatic breast cancer. Fraschini G; Fleishman G; Charnsangavej C; Carrasco CH; Hortobagyi GN Cancer Treat Rep; 1987 Nov; 71(11):1001-5. PubMed ID: 3677109 [TBL] [Abstract][Full Text] [Related]
36. Mitoxantrone for advanced breast cancer. Gupta P; Tandon R J Assoc Physicians India; 1992 Apr; 40(4):282. PubMed ID: 1452548 [No Abstract] [Full Text] [Related]
37. Mitoxantrone, fluorouracil plus L-leucovorin, and vinorelbine in pretreated advanced breast cancer. Colleoni M; Nelli P; Gaion F; Sgarbossa G; Manente P Oncology; 1995; 52(6):435-8. PubMed ID: 7478426 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. Dieras V; Extra JM; Bellissant E; Espie M; Morvan F; Pierga JY; Mignot L; Tresca P; Marty M J Clin Oncol; 1996 Dec; 14(12):3097-104. PubMed ID: 8955654 [TBL] [Abstract][Full Text] [Related]
39. First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: results of a phase II study. Llombart-Cussac A; Pivot X; Rhor-Alvarado A; Le Cesne A; Le Chevalier T; Tursz T; Spielmann M Oncology; 1998; 55(5):384-90. PubMed ID: 9732214 [TBL] [Abstract][Full Text] [Related]
40. Mitoxantrone, methotrexate and chlorambucil in metastatic breast cancer, a combination with relatively low subjective toxicity. Burghouts JT Neth J Med; 1990 Feb; 36(1-2):43-5. PubMed ID: 2314519 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]